Event Participants
Executives
3 Anurag Tantia, Atul Tantia, Kriti Tantia
Analysts
5 Abhishek Maheshwari, Anuj Kashyap, Parth Kotak, Sejal Bhattar, Soumya Raghuvanshi
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹126.2 crores | +18.2% YoY; driven by healthy patient volumes, improved occupancy, and favorable case mix across mature hospitals |
| EBITDA | ₹26.2 crores | EBITDA margin of 20.4%, up from 19% in FY26; supported by mature hospital resilience and new facility ramp-up |
| PAT | ₹12.7 crores | +66% YoY; PAT margin of 9.9%; reflecting strong operating leverage and reduced losses at Raipur |
| Network Occupancy | 45.5% | Including new Raipur facility; excluding Raipur, mature hospital occupancy at 58.07% |
| Mature Hospital Occupancy | 58.07% | Steady patient inflows; Dum Dum at 65% (vs 60% YoY), Salt Lake at 62% (vs 60% YoY) |
| ARPOB (Network) | ₹42,350 | Improved on specialized, high-acuity case mix; Salt Lake at ₹45,300, Dum Dum at ₹43,041, Agartala at ₹41,573 (+17% YoY) |
| Cash & Insurance Revenue Share | ~90% | Strong payer mix; minimal dependence on government schemes |
| Raipur Occupancy | 17% | Up from 7% YoY; on track for ~30% exit occupancy in FY27 |
| Raipur EBITDA Loss | -₹3 crores | Similar to Q4 FY26; expected to taper through the year |
| EBITDA Margin Guidance | ~21% (FY27) | 200 bps improvement YoY; translating to ₹110-115 crores EBITDA |
| Long-term ROE/ROCE Target | ~25% | Driven by occupancy increase, specialty mix shift, lower length of stay, and asset-light expansion |
Geographic & Segment Commentary
ILS Salt Lake (Flagship Tertiary): Continued strong performance with occupancy at 62% (up from 60% YoY) and ARPOB at ₹45,300 on favorable high-contributing surgery mix. Cumulative robotic procedures exceeded 800, reinforcing leadership in robotic-assisted surgeries; received DNB course approval in medical gastroenterology.
ILS Dum Dum: Remained the highest-occupied hospital in the network at 65% (vs 60% YoY); occupied beds at 71% in Q4 FY26 reflect seasonal variation. Renal transplant program surpassed 700 transplants; newly commissioned cardiothoracic and vascular surgery unit completed ~200 cardiac surgeries in 5 months; focus on neurosciences and high-end gastroenterology supporting ARPOB improvement.
ILS Agartala: Occupancy declined due to tribal elections restricting movement for ~1 month and conscious reduction in average length of stay (3.38 to 3.0 days), despite higher inpatient numbers. ARPOB grew 17% to ₹41,573 on higher-end tertiary care; July occupancy returned to ~51% with record monthly revenue; cancer care center completed 700+ radiation procedures; increasing patient inflows from Bangladesh.
ILS Howrah: Revenue grew 31% YoY with occupancy up 16%; Mako robotic knee replacement program strengthening orthopedic franchise. First corporate hospital in the micro-market; focus on converting patient habits from traveling to Kolkata, brand-building over doctor-branding, and adding departments/consultants.
ILS Raipur (Central India expansion): Occupancy improved to 17% from 7% YoY; recognized as NABH hospital in record 13 months; conducted first liver transplant within just over a year of commissioning (~10 expected in first year). Slight ARPOB dip to ₹42,300 (from ₹44,500 QoQ) due to limited Ayushman Bharat patients; insurance empanelments largely complete. Operating under asset-light model with developer-built premises on long-term lease (rental at mid-₹30s per sq ft).
Company-Specific & Strategic Commentary
Capacity Expansion: Construction of 155-bed Jamshedpur tertiary care hospital on schedule for commissioning in Q4 FY27 (possibly early FY28 if approvals delay); asset-light model with developer constructing to specifications on long-term lease. Evaluating seventh hospital opportunities in Tier-1/Tier-2 Eastern India cities including Cuttack, Ranchi, Patna, Banaras, and Prayagraj; network to exceed 1,000 beds within two years.
Clinical Excellence & Specialty Mix: Continued shift toward high-acuity quaternary care across all hospitals—transplants (renal, liver), robotic surgeries, interventional neurology, and cardiothoracic surgery. Specialty mix and case mix changes contribute 50-60% of ARPOB growth; annual inflation-linked tariff revisions (October) are small contributors.
Asset-Light Operating Model: Raipur and Jamshedpur developed on lease-based properties, reducing real estate investment and positively impacting ROCE. Not fixated on the model—acquisitions and greenfield remain options depending on location and pricing.
Talent & Retention: Doctor attrition in single digits (6-7% in Kolkata, ~10% in Agartala/Raipur due to geographic challenges). Retention strategies include financial/non-financial rewards, owned nursing college in Agartala, certified training programs, and strong academic focus across hospitals.
Government Payer Strategy: ~90% revenue from cash and insurance; deliberate avoidance of government schemes in West Bengal due to payment delays and lower ARPOB, which would dilute ROE/ROCE. Open to government patients if strategy warrants in the future.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin | ~21% for FY27 | 200 bps improvement YoY (from 19%); driven by mature hospital occupancy gains, ARPOB increase, and reduced Raipur losses |
| EBITDA | ₹110-115 crores (FY27) | Includes other income; based on operating leverage from improved occupancy and case mix |
| Raipur Occupancy | ~30% exit FY27 | Continued specialty expansion; breakeven expected around 20-month mark |
| Raipur EBITDA Loss | Tapering through FY27 | From -₹3 crores in Q1; reducing losses supporting overall margin expansion |
| Jamshedpur Commissioning | Q4 FY27 (late) | 155-bed tertiary care hospital; possibility of slip to early FY28 if approvals delayed; initial ARPOB expected ₹30,000-40,000, catching up to Kolkata levels (~₹42,000-43,000) as hospital matures; breakeven in ~24 months (20-24 months based on historical benchmarks) |
| Dum Dum Occupancy | Optimum levels by Q3 FY27 | 70%+ occupancy to become normal; cardiac and neurosciences driving growth |
| FY27 Revenue Growth | Growth trajectory maintained | Agartala July recorded highest-ever monthly revenue; Q2 seasonally favorable for healthcare |
| International Patients | Pre-disruption levels within 6 months | Policy changes in India and Bangladesh directing visa requests to specific hospitals; benefiting Agartala directly |
| Tariff Increases | Annual, October cycle | Inflation-linked tariff revisions; small contributor to ARPOB growth vs specialty mix (50-60%) |
Risks & Constraints
| Risk | Context |
|---|---|
| New Hospital Ramp-up Risk | Raipur at 17% occupancy (low base) and Jamshedpur not yet operational; losses at Raipur (-₹3 crores in Q1) expected to taper but timeline dependent on occupancy ramp to ~30% exit rate and breakeven by ~20-month mark. Jamshedpur commissioning subject to approval timelines, with potential slip to FY28. |
| Geographic/Geopolitical Disruptions | Agartala occupancy impacted by tribal elections in May restricted patient movement for ~1 month; July recovered to ~51% occupancy with record revenue. Bangladesh political/policy changes affected international patient inflows; normalization expected within 6 months. |
| Revenue Concentration in Eastern India | Expansion into Central India (Raipur) and new markets (Jamshedpur) introduces execution risk in unfamiliar geographies; Agartala has higher doctor attrition (~10%) due to geographic challenges. |
| Government Scheme Participation | Raipur's ARPOB slightly diluted by Ayushman Bharat patients (lower realization); limited insurance empanelment originally constrained case mix. As empanelments complete, ARPOB expected to stabilize/increase. |
| Competition for Talent | Doctor attrition higher in Agartala and Raipur (~10%) vs Kolkata (6-7%); mitigation through academic investment, training programs, and nursing college pipeline. |
| Asset-Light Model Dependency | Long-term leases (mid-₹30s per sq ft) for Raipur and Jamshedpur reduce capital intensity but create fixed rental obligations; model may not suit all future locations. |
Q&A Highlights
Agartala Occupancy and Geopolitical Impact
- Question: Despite geopolitical headwinds, how will Agartala improve occupancy? Are targets recalibrated? (Unidentified participant)
- Answer: Occupancy dip was due to tribal elections restricting movement for a month, not underlying demand. July average occupancy returned to ~51%, with one of the highest monthly revenues in hospital history. Original targets intact. (Anurag Tantia)
ARPOB Drivers - Mix vs Pricing
- Question: Is ARPOB increase driven by high-end treatments or price increases? (Abhishek Maheshwari, SkyRidge)
- Answer: No tariff increases during the quarter (annual hike in October). ARPOB improvement purely from case mix shift toward high-end tertiary care—cardiology, oncology, neurosciences. This is a sustainable strategy going forward. (Anurag Tantia)
Raipur Losses and Occupancy
- Question: What is Raipur's Q1 loss and expected exit occupancy? (Abhishek Maheshwari)
- Answer: Raipur loss at -₹3 crores (flat QoQ), expected to taper through the year. Exit occupancy target of ~30%. (Anurag Tantia)
Jamshedpur Debt and Commissioning
- Question: Has debt position changed due to Jamshedpur? (Parth Kotak, Plus91)
- Answer: Debt same as last year; Jamshedpur will add ~₹25 crores debt during FY27 as project progresses. (Anurag Tantia)
Government Payer Strategy (Ayushman Bharat)
- Question: With new West Bengal government, any plans to increase government segment revenue? (Anuj Kashyap, A3 Capital)
- Answer: No. Government patients come with payment delays and lower ARPOBs; hospitals don't need them to meet financial metrics. Strategy unchanged—would only consider if requirement arises. (Anurag Tantia)
Levers for 25% ROE/ROCE
- Question: What are the biggest levers to achieve 25% ROE/ROCE over 3-5 years? (Unidentified participant)
- Answer: Occupancy improvement, lower length of stay, and shift toward higher ARPOB procedures (50-60% of ARPOB growth from specialty mix). Asset-light expansion model reduces real estate investment, positively impacting ROCE. (Anurag Tantia)
Seventh Hospital - Cities and Mode
- Question: Have cities been shortlisted for the seventh hospital? Greenfield or acquisition? (Unidentified participant)
- Answer: Evaluating Tier-1/Tier-2 cities in Eastern India—Cuttack, Ranchi, Patna, Banaras, Prayagraj. Open to both greenfield and acquisition; depends on right location and pricing. (Anurag Tantia)
Asset-Light Model Clarification
- Question: What is meant by asset-light? (Abhishek Maheshwari)
- Answer: Raipur and Jamshedpur use developer-built premises customized to specifications on long-term rent (mid-₹30s per sq ft). Reduces real estate investment; more capital directed to medical assets. Not fixated on the model—location determines approach. (Anurag Tantia)
Dum Dum Occupancy Dip and Specialty Evolution
- Question: Why did Dum Dum occupancy drop from 71% in Q4 to 65%? What about specialty mix evolution? (Abhishek Maheshwari)
- Answer: Q4-to-Q1 seasonal variation; YoY improvement from 59.75% to 65%. Cardiac surgery unit (200 surgeries in 5 months), neurosciences, and high-end gastroenterology driving ARPOB improvement. Expect 70%+ occupancy to normalize by Q3 FY27. (Anurag Tantia)
Raipur ARPOB Decline and Jamshedpur Projections
- Question: Why did Raipur ARPOB fall QoQ, and what's Jamshedpur's expected trajectory? (Abhishek Maheshwari)
- Answer: Raipur ARPOB dipped from ₹44,500 to ₹42,300 due to limited Ayushman Bharat patients (lower realization); insurance empanelments now largely complete, ARPOB should maintain/increase. Jamshedpur initial ARPOB expected ₹30,000-40,000, catching up to ~₹42,000-43,000 as hospital matures; breakeven ~24 months (20-24 months based on historical performance). (Anurag Tantia)
Doctor Attrition and Talent Strategy
- Question: What are doctor attrition numbers and retention strategies? (Anuj Kashyap, A3 Capital)
- Answer: Single-digit attrition in Kolkata (6-7%); ~10% in Agartala/Raipur due to geographic challenges. Strategies include financial/non-financial rewards, owned nursing college in Agartala, certified training programs, and heavy investment in academics (DNB courses) attracting doctors. (Anurag Tantia)
FY27 EBITDA Trajectory
- Question: Is ₹30 crores EBITDA run-rate achievable going forward, translating to ₹110-120 crores annually? (Unidentified participant)
- Answer: Expect FY27 closing at ~21% EBITDA margins (vs 19% last year), translating to ~₹110-115 crores including other income. Driven by better mature hospital occupancy and reduced Raipur losses. (Anurag Tantia)
Medium-term Guidance
- Question: Would the company provide medium-term guidance on occupancy and mature hospital revenue growth? (Unidentified participant)
- Answer: No direct guidance provided; referred to MUFG for follow-up. Company avoids formal medium-term guidance commitments. (Anurag Tantia)
Key Takeaway
GPT Healthcare delivered a robust Q1 FY27 with revenue of ₹126.2 crores (+18.2% YoY) and PAT of ₹12.7 crores (+66% YoY), driven by mature hospital occupancy gains (58.07% ex-Raipur), ARPOB improvement to ₹42,350 on favorable specialty mix, and disciplined cost management. Expansion into Central India continues with Raipur occupancy tripling to 17% (target ~30% exit, breakeven ~20-month mark, -₹3 crores loss tapering through FY27), while Jamshedpur's 155-bed hospital remains on schedule for late Q4 FY27 commissioning under an asset-light model with ~₹25 crores incremental debt. Management guided to ~21% FY27 EBITDA margins (₹110-115 crores) and reiterated the 25% long-term ROE/ROCE target, supported by the specialty mix shift toward high-acuity care (contributing 50-60% of ARPOB growth), lower length of stay, and asset-light expansion. Agartala's temporary occupancy dip on election-related disruption recovered in July (51% occupancy, record revenue) with Bangladesh patient inflows expected to reach pre-disruption levels within six months. Key watch points include Raipur's ramp-up trajectory, Jamshedpur commissioning timing, and the seventh hospital announcement in Eastern India cities (Cuttack, Ranchi, Patna, Banaras, Prayagraj), which will expand network capacity beyond 1,000 beds over the next two years.